The molecular clones pSPeiav19 and p19/wenv17 of equine infectious anemia virus (EIAV) differ in env and long terminal repeats (LTRs) and produce viruses (EIAV 19 and EIAV 17 , respectively) of dramatically different virulence phenotypes. These constructs were used to generate a series of chimeric clones to test the individual contributions of LTR, surface (SU), and transmembrane (TM)/Rev regions to the disease potential of the highly virulent EIAV 17 . The LTRs of EIAV 19 and EIAV 17 differ by 16 nucleotides in the transcriptional enhancer region. The two viruses differ by 30 amino acids in SU, by 17 amino acids in TM, and by 8 amino acids in Rev. Results from in vivo infections with chimeric clones indicate that both LTR and env of EIAV 17 are required for the development of severe acute disease. In the context of the EIAV 17 LTR, SU appears to have a greater impact on virulence than does TM. EIAV 17SU , containing only the TM/Rev region from the avirulent parent, induced acute disease in two animals, while a similar infectious dose of EIAV 17TM (which derives SU from the avirulent parent) did not. Neither EIAV 17SU nor EIAV 17TM produced lethal disease when administered at infectious doses that were 6-to 30-fold higher than a lethal dose of the parental EIAV 17 . All chimeric clones replicated in primary equine monocyte-derived macrophages, and there was no apparent correlation between macrophage tropism and virulence phenotype.
Equine infectious anemia virus (EIAV) is a macrophagetropic lentivirus of horses
. The virus differs from the feline, simian, and human immunodeficiency viruses (FIV, SIV, and HIV, respectively) in that lymphocytes are not targets of virus replication and that infected animals do not develop severe immunodeficiency (32) . Following exposure to the virus, an acute disease episode of relatively short duration generally occurs within 1 week to 1 month. Acute disease is characterized by fever, anemia, thrombocytopenia, central nervous system depression, and anorexia (reviewed in references 19 and 41) . The acute disease episode is generally mild, but horses will occasionally develop a particularly severe, fatal form of acute disease that is characterized by a high-titer viremia and very high body temperature. Animals recovering from the acute disease episode may enter the chronic or persistent phase of EIA, which is characterized by periodic episodes of clinical illness. Most infected horses gain immunologic control of virus replication, becoming inapparent carriers.
EIAV antigenic and genomic variations have been previously examined at length (1, 3, 6, 17, 18, 21, 23, 24, 33, 35, 39, 40, 45, 46) . Studies of env gene variation demonstrate that infected animals maintain the virus as a quasispecies, as has been previously documented for other lentiviruses (17, 18, 23, 24, 26, 34, 35, 45, 46) . Accumulation of mutations in specific variable domains of the surface (SU) unit protein allows the virus to evade or escape neutralizing antibodies (14, 15) . Genetic variation in other regions of the EIAV genome has also been described previously. We and others have demonstrated the influence of long terminal repeat (LTR) sequences on the growth characteristics of EIAV (25, 31, 36) . Genetic analysis of rev during long-term infection suggests that rev variation may influence virus expression, affecting long-term viral persistence (3, 4) .
Previous studies of EIAV genetic variation have focused largely on understanding the virus-host interactions that result in chronic disease and viral persistence rather than on defining the determinants of virulence. For the present study, we used infectious molecular clones of EIAV to examine the genetic basis of two very different virulence phenotypes that have been described previously (37, 38) . EIAV 19 is a virus stock derived from the infectious molecular clone pSPeiav19. EIAV 19 replicates in primary fetal equine kidney, equine dermis, and equine monocyte-derived macrophages (eMDM) as well as in the feline embryonic adenocarcinoma and Cf2Th cell lines (38) . We have observed that EIAV 19 causes no clinical disease, even when administered to ponies at high doses (38) .
To generate a genetically defined virulent virus, pSPeiav19 was used as the backbone to produce a set of clones in which env and LTRs were replaced by sequences obtained directly from the highly virulent Wyoming field strain of EIAV (37) . One construct, p19/wenv17, has been described previously, and virus derived from this clone (designated EIAV 17 ) causes severe acute disease in our Shetland pony model (37) . EIAV 17 replicates only in eMDM, a characteristic shared by field strains of EIAV (5) . The acute virulence phenotype of EIAV 17 is useful for studies in which the availability of experimental animals is limited.
Sequence differences between clones pSPeiav19 and p19/ wenv17 are limited to an approximately 2-kb fragment of env and the viral LTRs. Virus stocks derived from both pSPeiav19 and p19/wenv17 replicate to a high titer, with cytopathic effects, in eMDM (37), so it is unlikely that the dramatic difference in their virulence phenotypes is due solely to macrophage tropism. These clones provide an ideal starting point to locate those genes or regions that play major roles in virulence. In this report, we describe the construction and testing of several new infectious molecular clones of EIAV that we have used to determine the contributions of env and LTRs to the virulence phenotype of EIAV 17 and demonstrate that both SU and LTRs contain virulence determinants.
MATERIALS AND METHODS
Clone construction. Infectious molecular clones described in this report are depicted in Fig. 1. pSPeiav19 (Fig. 1A) , p19/wenv17 (Fig. 1B) , and p19/wyoLTR (Fig. 1C) have been described previously (36) (37) (38) . The new construct p17env/19 ( Fig. 1D) contains an env gene fragment from p19/wenv17, but its LTRs are derived from pSPeiav19. p17env/19 was constructed by using a combination of PCR and conventional cloning. PCR was used to generate a 338-bp fragment containing nucleotides (nt) 7910 to 8231 from pSPeiav19 using primers WS1 (5Ј-TGTGGGGTTTTTATGAGGGG-3Ј) and 8211R1 (5Ј-CGCGGTCGACGA ATTCTGTAGGATCTCGAACAGAC-3Ј) (Fig. 2) . Primers 7582 (5Ј-TAAGG ACCCTTGGTG-3Ј) and 91 (5Ј-GCCTAGCAACATGAGCT-3Ј) were used to generate a 428-bp fragment (nt 7587 to 8014) from p19/wenv17. The two PCR products overlap by 107 identical nt between the oligonucleotides WS1 and 91. These two products, and primers 8211R1 and 7611 (5Ј-CCCCCCCCGTCGAC FIG. 1. Schematic representation of clones and the EIAV genome. (A through G) Open boxes represent the sequence of pSPeiav19 (GenBank accession number U01866 [38] ). Solid black boxes represent sequences derived from the Wyoming field strain that were used to generate the p19/wenv17 clone (GenBank accession number AF028232 [37] 17 LTR sequences. The underlined region is the transcriptional enhancer. The sequence differences in this region result in the presence of a unique set of transcription factor binding sites for each virus; similar EIAV LTRs have been previously described and mapped by others (28, 29) . The arrows represent oligonucleotide primers used in PCR to facilitate the construction of p19/wyoLTR. The numbering scheme is based on the position of the 3Ј LTR from clones pSPeiav19 and p19wenv/17. (Fig. 1E ), we started with p19/wyoLTR (36), which had been digested with NheI to remove a 2.79-kbp pol-env fragment (Fig. 1G) . The corresponding NheI fragment was isolated from p19/wenv17 and ligated to the prepared vector. The two NheI fragments share sequences from the 5Ј NheI site through the SphI site but differ from the SphI site to the 3Ј NheI site; thus, the NheI fragment swap effectively places the SphI-to-3Ј-NheI fragment from p19/wenv17 onto the p19/wyoLTR background. Clone p19Nhe/17 ( Fig. 1F) derives sequences from the 3Ј NheI site through the 3Ј LTR from p19/wenv17. This plasmid was prepared by starting with clone p19/wenv17, removing its 2.79-kb NheI fragment, and replacing it with the corresponding NheI fragment from pSPeiav19. All clones were analyzed by restriction enzyme digestion and partial DNA sequence analysis in order to check that the desired genetic swaps and replacements were present. All clones were constructed and maintained in a derivative of the low-copy-number vector pLG338 (10) .
Virus stocks. To generate infectious virus, plasmid DNA was used to transfect D17 cells (ATCC CCL-183) by using a calcium phosphate transfection kit (Invitrogen) as described previously (37) , and culture supernatants were collected at 24, 48, and 72 h. Culture supernatants were tested for the presence of reverse transcriptase (RT), as described previously (13) One-milliliter aliquots of D17 cell supernatants were passed onto eMDM to generate virus stocks. The eMDM were recovered and maintained as described previously (44) .
The 50% infective dose (ID 50 ) for eMDM was also determined for each virus stock. Cells were plated in poly-D-lysine-coated 12-well dishes (BD Biosciences), infected 4 days postplating, and maintained for 11 days postinfection (p.i.). Virus was concentrated from culture supernatants by centrifugation; the presence of virus was determined by RT assay. RT values of greater than three times that of uninfected control cultures were considered positive for virus growth.
To serve as another indicator of viral infectivity, a real-time Taqman PCR assay was used to determine the provirus copy numbers in eMDM at 24 h p.i. Cells were lysed, and total DNA was purified by using a QIAmp tissue kit (Qiagen). A Taqman real-time PCR assay was performed on a Bio-Rad Icycler machine as follows. Each 50-l reaction contained 1ϫ reaction buffer (Applied Biosystems) without MgCl 2 , 5.5 mM MgCl 2 , 0.3 mM deoxynucleotide triphosphates, 0.3 M upstream primer (5Ј-TTCCCATGACAGCAAGGTTT-3Ј), 0.3 M downstream primer (5Ј-TCCATTGTCTATATGTCTGCCTAAA-3Ј), 0.07 M Taqman probe (5Ј-FAM-CAAAAGCAGGCTCCATCTGTCTTTCTCTAG GACT-TAMRA-3Ј), 5 to 10 g of DNA template or water control, and 1.25 U of AmpliTaq Gold (Applied Biosystems). Cycling parameters were 95°C for 30 s and 58°C for 1 min (40 cycles). DNA standards consisted of pSPeiav19 plasmid DNA at 10 2 to 10 6 molecules per reaction in duplicate. Cell DNA samples were analyzed in duplicate, and real-time data were analyzed by using Bio-Rad Icycler software.
Animal studies. Animal studies complied with all relevant federal guidelines and institutional policies. Virus stocks were used to infect Shetland ponies as previously described (37) . Animals inoculated with the following virus stocks received a virus dose of 2 ϫ 10 5 counts per minute (cpm) of RT activity: EIAV 17E/19L , EIAV 19/WYOLTR , and EIAV 17TM . EIAV 17SU was inoculated at a dose of 10 5 cpm of RT activity. Rectal temperatures of infected animals were monitored twice daily. Blood samples were obtained pre-and postinfection for determination of complete blood counts. Disease episodes were defined as periods of increased body temperature. Blood and serum samples were collected to quantify virus, to monitor the development of antiviral antibody, and for recovery of viral genomes. Enzyme-linked immunosorbent assay (ELISA) to detect a transmembrane peptide was performed by using a commercial assay (obtained from Centaur, Inc.). Agar gel immunodiffusion assays were performed as described previously (9) . Viral genome fragments were amplified from blood samples collected within 2 weeks p.i., cloned, and sequenced to confirm the identity of the infecting virus stocks.
RESULTS
In previous studies, we demonstrated a difference in the ability of EIAV 19 and EIAV 17 -derived from two infectious molecular clones, pSPeiav19 and p19/wenv17, respectively-to produce disease in Shetland ponies. EIAV 19 fails to produce clinical symptoms, even when administered to ponies at doses of up to 10 6 cpm of RT activity (38) . In contrast, EIAV 17 , which contains env and LTR sequences derived from the Wyoming field strain of EIAV, induces severe disease by two weeks p.i. when administered at 10-to 20-fold-lower doses (37) . As illustrated in Fig. 1 , these two clones share approximately 5.4 kb of sequence, differing only in their LTRs (Fig. 2) and env/rev regions (Fig. 3) . Regions in common include gag, pol, tat, S2, and the amino terminus of env. The shared env region has a length of 438 bp, encompassing the first 146 amino acids of the env open reading frame and the first coding exon of rev. To further investigate the genetic region(s) responsible for the different virulence phenotypes, we constructed additional clones combining defined regions of the pSPeiav19 and p19/wenv17 genomes.
Contribution of env and LTR sequences to virulence phenotype. We first assayed the individual contributions of the Wyoming-derived LTR and env sequences to the virulence phenotype of EIAV 17 . We constructed p17env/19 ( Fig. 1D) , which contains two complete LTRs from the avirulent clone pSPeiav19 in combination with the env region from the virulent p19/wenv17. Figure 2 shows the primers used in a PCR strategy to facilitate the LTR replacement. The EIAV 19 LTR was swapped for the EIAV 17 LTR in an identical region of 107 bp that begins just 3Ј to the polypurine tract. The two LTRs differ at 16 positions that fall within the enhancer region in U3 (Fig. 2) and confer changes in previously mapped transcription factor binding sites (28, 29) . As shown in Table 1 , EIAV 17E/19L , derived from clone p17env/19, replicates in eMDM to produce a virus stock with RT activity equivalent to that of the parental EIAV 17 virus. When tested in vivo, EIAV 17E/19L failed to produce a febrile episode during the first 45 days p.i. (Fig. 4B) ; however, the infected animal seroconverted by day 18 p.i. While only one animal was inoculated with EIAV 17E/19L , the virus dose (as determined by RT activity) was twofold higher than the dose of EIAV 17 that produced severe disease episodes (requiring euthanasia) in two animals (Fig. 4A) . We recently determined ID 50 titers in eMDM for each of the virus stocks tested in animals ( Table 1) . By this criterion, EIAV 17E/19L was administered at an infectious dose that was 2.5-fold higher than the lethal dose of EIAV 17 , suggesting that the Wyomingderived LTR makes an important contribution to the virulence phenotype of EIAV 17 .
Clone p19/wyoLTR (Fig. 1C ) derives its LTRs from the virulent parent p19/wenv17 and derives its env/rev sequences from the avirulent parent pSPeiav19, as described previously (36) . As shown in Table 1 , EIAV 19/WYOLTR , derived from clone p19/wyoLTR, replicates in eMDM to produce virus stocks with RT activity equivalent to that of EIAV 17 . EIAV 19/WYOLTR was used to infect two animals, whose clinical profiles are shown in Fig. 4C and D Fig. 3 . Therefore, we next examined the relative contribution of SU versus that of the TM/rev region to the virulence phenotype of EIAV 17 . We constructed p17Nhe/19/wyoLTR and p19Nhe/17, which contain only the SU or only the TM/Rev region from the virulent parent, respectively (Fig. 1) . Both constructs derive LTRs from the virulent parent and share common gag, pol, tat, and S2 sequences with both parents. The virus derived from p17Nhe/ 19/wyoLTR (designated EIAV 17SU ) shares amino acids 147 to 444 of SU with EIAV 17 . Note that the first 438 bp of SU is shared by both the virulent and avirulent parents and that this region encodes the first 146 amino acids of SU as well as the first coding exon of rev (Fig. 3) . The first 19 amino acids of TM of EIAV 17SU are also derived from the virulent parent, while the remainder of TM and the second coding exon of rev are from the avirulent parent. EIAV 17SU was used to infect Shetland ponies (results shown in Fig. 4E and F) . Both ponies experienced acute febrile episodes. Pony E2063 had a single febrile episode at days 10 to 12 p.i. The febrile episode resolved, and the animal maintained a normal body temperature for the next 2 months. Pony E2064 also experienced acute disease but with somewhat different characteristics. A day of elevated body temperature was recorded on day 10 p.i. and again at day 20 p.i. A more notable and extended febrile episode occurred at days 30 to 32 p.i. The body temperature then remained normal through the next 75 days p.i. While disease episodes were observed, it should be noted that they were less severe than those previously observed in ponies receiving EIAV 17 (Fig. 4A) (37) ; note also that the infecting dose of EIAV 17SU , as determined by two different infectivity assays (ID 50 and initial provirus copy number), was up to 30-fold greater than that of the EIAV 17 parent (Table 1) .
EIAV 17TM (from construct p19Nhe/17 [ Fig. 1F] ) shares amino acids 20 to 417 of TM and shares its overlapping rev sequences with virulent EIAV 17 . The clinical profiles of two animals infected with this virus are presented in Fig. 4G and H. These animals seroconverted at 10 and 21 days p.i., similar to the results observed for EIAV 17SU -infected animals, but body temperatures remained normal for more than 50 days p.i. Results of infectivity assays show that at an inoculum of 2 ϫ 10 5 cpm of RT activity, the ponies received 6-to 20-fold more infectious virus (as measured on eMDM by ID 50 and provirus   FIG. 3 . SU, TM, and Rev amino acid comparisons. The EIAV 19 sequence is shown above; EIAV 17 residues that differ are shown below. V2 through V8 indicate previously defined variable regions of EIAV SU (24) . The approximate positions of the SphI and NheI restriction enzymes used to construct EIAV 17SU and EIAV 17TM are shown. Coding exon 1 of rev is in the same reading frame as SU and is shown by the heavy underline. Exon 2 of rev is in an alternate reading frame, and the translation is shown in the bracketed region.
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on October 30, 2017 by guest http://jvi.asm.org/ copy number) relative to the lethal dose of EIAV 17 . This finding indicates that the TM/rev region alone is not sufficient to account for the observed virulence phenotype of EIAV 17 . By all criteria used to determine the titer of our virus stocks, both EIAV 17SU and EIAV 17TM were administered to ponies at doses equivalent to or higher than the lethal dose of EIAV 17 , yet neither induced acute febrile episodes requiring euthanasia.
DISCUSSION
We generated a series of infectious molecular clones of EIAV in order to map the major virulence determinants of this lentivirus. Our focus was to identify genetic regions that influence the development and/or severity of acute disease. These studies were facilitated by the availability of genetically related clones (pSPeiav19 and p19/wenv17) that produce viruses (EIAV 19 and EIAV 17 ) carrying different virulence phenotypes. The parental viruses and all of the new chimeric viruses replicate in eMDM with cytopathic effects. The RT titers of the new virus constructs were generally comparable to those of the parental clones (Table 1) . Pony inocula were based upon RT activity; however, we subsequently determined minimal infectivity titers of the stocks used for the infections. ID 50 s per cpm were determined by using primary eMDM from a single donor animal. Unfortunately, the life span of eMDM under our standard culture conditions is limited to approximately 3 weeks, an experimental endpoint that might not allow adequate comparison of viruses with similar infectivity but different replication kinetics. To attempt to address this possibility, we performed a single experiment in which provirus copy numbers present at 24 h p.i. were determined by real-time PCR. As shown in Table  1 , the relative amount of provirus at 24 h p.i. per cpm of inoculum paralleled the ID 50 s per cpm for EIAV 17 , EIAV 17SU , and EIAV 17TM . With one exception (EIAV 19/WYOLTR ), the ID 50 s of the tested viruses were equivalent to or greater than that of the parental EIAV 17 virus. Since none of the chimeric viruses produced disease severity equivalent to that produced by EIAV 17 , it is clear that the ability to replicate in eMDM per se is not a helpful indicator of the potential for the development of severe acute disease by EIAV.
Our in vivo assays consisted of using a small number of experimental animals and performing infections with high doses of virus. Using these parameters, we showed that both the env and LTRs derived from the Wyoming field strain were required for the virulence phenotype of EIAV 17 . Replacement of either the Wyoming-derived LTRs or env with those of the avirulent strain yielded a virus that caused no acute disease in our experimental system. EIAV 17 and EIAV 17E/19L differ only in their LTR sequence and display dramatically different virulence phenotypes. The two LTRs have multiple sequence differences that alter transcription factor binding motifs (Fig.  2) . Detailed descriptions of EIAV LTR sequences similar to those in the present study have been reported previously (28, 29) , but to our knowledge, direct in vivo comparisons of these two LTRs have not been described. We have previously demonstrated that the Wyoming LTR neither drives transcription of a reporter gene construct nor supports virus replication in fibroblasts (36) . This finding explains the selection of variant LTRs (similar to the EIAV 19 LTR) during adaptation to growth in fibroblasts. It has also been shown that most field strains of EIAV have LTRs that closely resemble the Wyoming strain consensus and that there is little LTR variation when virus containing a Wyoming-like LTR is examined over time in vivo (26) . Finally, Wyoming-like LTRs emerge in horses infected with culture-adapted virus stocks (35) . These data strongly suggest that Wyoming-like LTR sequences are favored in vivo. Remaining unclear are the critical interactions between viral LTR and host cell that favor the Wyoming LTR in vivo and allow for disease expression from EIAV 17 but not EIAV 17E/19L . A higher expression level in vivo in circulating monocytes or tissue macrophages may lead to an increased virus burden in the infected animal; however, an in vitro difference in replicative ability is not apparent. Alternatively, the EIAV 17 LTR might facilitate virus replication in cells other than monocytes and macrophages, and this ability may contribute to the virulence phenotype. In this regard, Maury et al. (30) previously demonstrated the replication of EIAV in primary equine endothelial cells. Replication efficiency was strain dependent, with three of four different strains replicating in umbilical cord and renal artery endothelial cells. Interestingly, the Wyoming strain of EIAV was the one tested strain that failed to replicate in these cells (30) . It is also possible that subtle but important differences in the regulation of virus expression in vivo are affected by the LTR sequence. Future fine-structure mapping studies of the EIAV LTR will be necessary in order to define the contributions of specific transcription factor binding motifs to the virulence phenotype of EIAV 17 .
The LTR sequence is not the sole virulence determinant of EIAV 17 ; the Wyoming-derived env gene also contributes to its virulence phenotype. Forty-seven amino acid differences are found in the env regions EIAV 17 and EIAV 19 . Thirty of these are located in SU; 17 differences are found in TM. Rev sequences differ by eight amino acids in the second coding exon. To delineate the differences that exert the highest impact on virulence, we chose to examine env in the context of the Wyoming-derived LTR. Using a convenient NheI restriction enzyme site, we generated EIAV 17SU , which derives SU, and the first 19 amino acids of TM, from the virulent parent. Due to the method of generating EIAV 17 , EIAV 17SU shares most of TM and all of its rev sequences with the avirulent parent. A high dose of EIAV 17SU caused acute disease in our two test animals. However, the disease was not as severe as animals infected with EIAV 17 (37) , even though the EIAV 17SU inocula, as determined by ID 50 , were severalfold greater than those of EIAV 17 . This finding strongly suggests that the presence of TM/rev sequences from the avirulent parent attenuates the overall virulence phenotype. There are 30 amino acid differences in SU between the avirulent virus, EIAV 19 , and both of the acutely virulent viruses (EIAV 17 and EIAV 17SU ). The clones contain very divergent V3 sequences. V3 is the principal neutralizing domain (PND) of EIAV (2) and is a region of extensive sequence variation in vivo (23, 24, 35, 45, 46) . Both insertions and deletions in the EIAV PND are common, and viruses that totally lack the PND have been recovered previously (24) . EIAV 17 and EIAV 19 also differ in the previously defined V4 through V6 regions of SU (24) . V4 is a short variable region of five amino acids (NDTDT in EIAV 19 and NDSDT in EIAV 17 ). Both viruses have a potential N-linked glycosylation site in V4, and it seems unlikely that the T-to-S substitution would play a major role in the virulence phenotype. The V5 region of EIAV has been defined as a 10-amino-acid sequence (24) . The V5 sequence of EIAV 17 , but not that of EIAV 19 (23, 24, 46) . EIAV 17 and EIAV 19 also diverge extensively in the V6 region of SU, where they differ by 8 of 13 amino acids (positions 308 to 320). A functionally equivalent substitution of V to I occurs near V6, at position 305, and two functionally equivalent amino acid substitutions occur within V6 (Y309S and A311I). A striking difference in V6 between EIAV 19 and EIAV 17 is the presence in EIAV 17 of two potential N-linked glycosylation sites that are generated by a D-to-N substitution at position 308 and by R-to-N and L-to-T substitutions at positions 314 and 317. Examination of this region in persistently infected animals shows a number of N-linked glycosylation sites in the V6 region that varies from 0 to 2 (23, 45, 46) . The two clones have similar V7 sequences and differ in V8 by one amino acid.
The evolution of the V3 and V4 regions of EIAV SU have been previously linked to the development of neutralization resistance phenotypes during long-term infection (17) , and a neutralizing monoclonal antibody has been mapped to V5 (2)-strong indications that these regions evolve in response to immune pressures. The V6 region of EIAV SU has not yet been demonstrated to play a role in virus neutralization, as no neutralizing antibodies to this region have been identified (17) ; however, only a limited number of such antibodies have been tested. There is presently little information regarding specific functions of various SU domains. For example, cellular receptors and/or coreceptors for EIAV have not been identified, and no direct effects of purified EIAV SU on cell function or disease processes have been reported. While the present study suggests a role for SU in the development of acute disease, additional studies are required so as to clarify its role in disease expression.
Both of the acutely virulent viruses (EIAV 17 and EIAV 17SU ) also share the first 20 amino acids of TM. This region differs between the virulent and avirulent viruses at two positions (I4V and I7V) that lie in the fusion peptide of EIAV TM (based on similarity to SIV and HIV TM proteins). As these substitutions do not alter the hydrophobic nature of the domain, it would be surprising if they played a major role in the virulence phenotype of EIAV 17 .
EIAV 17TM shares amino acids 20 to 417 of TM (and the second coding exon of rev) with the virulent EIAV 17 . Virus derived from EIAV 17TM failed to cause an acute febrile episode in either of two infected animals, suggesting that TM/Rev is not solely responsible for the virulence phenotype of EIAV 17 . Our results do suggest a role for TM/Rev in virulence, however, as EIAV 17SU is less virulent than is the EIAV 17 parent. Comparison of the TM sequences between the avirulent and acutely virulent viruses reveals 17 amino acid differences. None of the amino acid substitutions in TM change the position or number of N-linked glycosylation sites, and hot spots for variation in TM have not been noted.
The role of env sequences in lentivirus virulence has been clearly demonstrated in simian-human immunodeficiency virus (SHIV)-infected rhesus macaques (7, 8, 11, 12, 16, 20, 22, 27, 43) . As few as 12 amino acid differences in the env sequence are sufficient to change pathogenic potential of SHIV clones (43) . Most of the env changes that arise with increased virulence are localized to gp120 variable regions; changes in the number and position of N-linked glycosylation sites are common (7, 8, 16, 27, 43) . Some measurable differences in virulent SHIVs that have been attributed to env sequence changes include fusogenicity, resistance to neutralization, and increased replicative potential (7, 8, 43) . During the present study, we determined that infectivity of EIAV for eMDM is not a reliable indicator of virulence. However, we have not yet compared the replication kinetics of our virus stocks. In addition, the development of acute disease generally occurs prior to the development of a detectable immune response; thus, resistance to neutralization is unlikely to play a role in this process. The possibility that other env-mediated biologic differences correlate with virulence is currently under investigation.
All of the EIAV clones in this study are identical in the first coding exon of rev, which specifies the nuclear export sequence. However there are eight amino acid differences between EIAV 19 and EIAV 17 in the second coding exon of rev (Fig. 3) . Belshan et al. (3, 4) analyzed the rev quasispecies present over time in a horse infected with the Wyoming strain of EIAV. EIAV 17 rev is very similar (differing by only one amino acid, E37G) to the predominant rev sequence in infectious Wyoming virus stocks (3). This rev sequence was present during the acute febrile episode, was not recovered during chronic disease, and then reappeared during a long afebrile period (3) . In contrast, the rev of EIAV 19 is similar to rev variants that predominated during late-stage inapparent carrier infection (800 days p.i.). Both the virulent and avirulent clones thus contain rev sequences that have been found in a natural infection but that may confer a different replication potential or phenotype to the virus.
We are continuing to examine the role of env in EIAV virulence by generating additional molecular clones and by monitoring env evolution in rapid-passage experiments.
